Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr. The present invention is further directed to an acetate salt an L-lactate salt and an L-aspartate salt of sertraline pharmaceutical compositions thereof and methods of using that salt for treating various conditions and disorders. The present invention is also directed...

The invention provides the substantially geometrically and optically pure trans-steroisomeric form of a compound of formula (I) wherein R1 is H or C1-C4 alkyl together with processes for its preparation. The compounds are intermediates for the preparation of the antidepressant agent known as sertraline.

The invention provides the substantially geometrically pure cis-stereoisomeric form of a compound of formula (I) and the substantially geometrically and optically pure cis-stereoisomeric form of a compound of formula (II) wherein R1 is H or C1-C4 alkyl together with processes for their preparation. The compounds are intermediates for the preparation of the antidepressant agent known as sertraline.